Emergent BioSolutions Inc. (NYSE:EBS) Holdings Decreased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. lessened its stake in Emergent BioSolutions Inc. (NYSE:EBS) by 88.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,401 shares of the biopharmaceutical company’s stock after selling 62,677 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Emergent BioSolutions were worth $70,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. SeaCrest Wealth Management LLC boosted its holdings in shares of Emergent BioSolutions by 3.2% in the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after acquiring an additional 3,705 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 4,409 shares in the last quarter. CWM LLC boosted its stake in Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions during the 2nd quarter valued at $41,000. Finally, Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions in the 2nd quarter worth $68,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on EBS shares. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Finally, Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Trading Down 1.5 %

Shares of NYSE EBS opened at $9.01 on Friday. The business has a fifty day simple moving average of $9.38 and a 200-day simple moving average of $8.54. The company has a market cap of $488.16 million, a price-to-earnings ratio of -2.20 and a beta of 1.59. Emergent BioSolutions Inc. has a 12 month low of $1.42 and a 12 month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.